U.S. flag

An official website of the United States government

NM_000492.4(CFTR):c.3139+18C>T AND not specified

Germline classification:
Benign (2 submissions)
Last evaluated:
Mar 13, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000507770.14

Allele description [Variation Report for NM_000492.4(CFTR):c.3139+18C>T]

NM_000492.4(CFTR):c.3139+18C>T

Genes:
CFTR:CF transmembrane conductance regulator [Gene - OMIM - HGNC]
LOC111674472:DNase I hypersensitive sites in introns 16 and 17a of CFTR [Gene]
Variant type:
single nucleotide variant
Cytogenetic location:
7q31.2
Genomic location:
Preferred name:
NM_000492.4(CFTR):c.3139+18C>T
HGVS:
  • NC_000007.14:g.117610687C>T
  • NG_016465.4:g.149904C>T
  • NG_056128.2:g.3741C>T
  • NM_000492.4:c.3139+18C>TMANE SELECT
  • LRG_663t1:c.3139+18C>T
  • LRG_663:g.149904C>T
  • NC_000007.13:g.117250741C>T
  • NM_000492.3:c.3139+18C>T
Links:
dbSNP: rs147945812
NCBI 1000 Genomes Browser:
rs147945812
Molecular consequence:
  • NM_000492.4:c.3139+18C>T - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000052168Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Benign
(Mar 27, 2018)
germlineclinical testing

PubMed (8)
[See all records that cite these PMIDs]

Citation Link,

SCV005196620Clinical Genetics Laboratory, Skane University Hospital Lund
criteria provided, single submitter

(ACMG Guidelines, 2015)
Benign
(Mar 13, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis.

Pignatti PF, Bombieri C, Marigo C, Benetazzo M, Luisetti M.

Hum Mol Genet. 1995 Apr;4(4):635-9.

PubMed [citation]
PMID:
7543317

F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis.

Gamaletsou MN, Hayes G, Harris C, Brock J, Muldoon EG, Denning DW.

J Asthma. 2018 Aug;55(8):837-843. doi: 10.1080/02770903.2017.1373808. Epub 2017 Oct 16.

PubMed [citation]
PMID:
29035608
See all PubMed Citations (9)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000052168.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (8)

Description

Variant summary: The CFTR c.3139+18C>T variant involves the alteration of a non-conserved intronic nucleotide. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0014 in 276326 control chromosomes in the gnomAD database, including 1 homozygote. This frequency is not higher than expected for a pathogenic variant in CFTR causing Cystic Fibrosis (0.0014 vs 0.013), allowing no conclusion about variant significance. The c.3139+18C>T has been reported in the literature in an individual presented with mild Cystic Fibrosis, however this patient was compound heterozygous for two deleterious CFTR variants, c.1083delG (p.Trp361fsX8) and c.2291delG (p.Arg764fsX7), suggesting the variant of interest to be in the benign spectrum (Romey_1994). In addition, the variant was found in trans with F508del in an individual, who did not have CF (Gamaletsou_2017). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as benign. Multiple published reports cite the variant as "polymorphism" (Bombier_1998; Romey_1994; Pignatti_1995). Based on the evidence outlined above, the variant was classified as benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Clinical Genetics Laboratory, Skane University Hospital Lund, SCV005196620.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 26, 2024